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Volume 166, Number 6As opposed to ST-elevation myocardial infarction
(STEMI), electrocardiographic (ECG) changes are often
nondiagnostic in non–ST-elevation MI (NSTEMI), and
measuring cardiac troponin levels is an important
diagnostic cornerstone.1,2 Despite being very sensitive
and specific markers for myocardial injury, troponins
are not specific for acute MI.3,4 The recently introduced
high-sensitivity cardiac troponin (hs-cTn) assays have
substantially improved the early diagnosis of acute MI in
comparison with the conventional troponin (cTn)
assays, but at the cost of a lower specificity.5,6
Therefore, it is often challenging to distinguish MI
from other disorders that result in elevated troponin
levels, such as myocarditis, pulmonary embolism (PE),
or Takotsubo cardiomyopathy (ie, noncoronary myo-
cardial disease).4,7
An important component of the universal definition of
acute MI is a typical rise and/or fall of cardiac troponin
with at least 1 value above the 99th percentile of a
reference population, but the magnitude of this rise and
fall has not been defined.1 Recent studies have shown
that discriminating between acute MI and noncoronary
myocardial disease can be improved by using algorithms
that combine baseline hs-cTn values with absolute or
relative changes over time. Limitations of these studies
are that the final diagnosis of acute MI was adjudicated
based on available clinical data, including the conven-
tional troponin assay, and routine noninvasive imaging
was not used. Furthermore, these studies were designed
retrospectively.4
Invasive coronary angiography (ICA) remains necessary
to distinguish between acute MI and noncoronary
myocardial disease, predisposing the latter to unneces-
sary ICA, aggressive antithrombotic, and antiplatelet
therapy. This potentially increases the length of hospital-
ization, number of complications, and health care costs.
Noninvasive imaging techniques can be used to differen-
tiate between coronary and noncoronary myocardial
disease and direct patient management.8
Delayed-enhancement cardiovascular magnetic reso-
nance imaging (DE-CMR) is a well-validated technique for
the diagnosis of irreversible myocardial damage, both in
ischemic and in nonischemic heart disease.9,10 An acute
coronary syndrome can be accurately detected by using a
CMR protocol comprising cine imaging, T2-weighted
(T2), myocardial perfusion, and DE imaging,
11,12 and
distinguished from noncoronary myocardial disease.13,14
Computed tomography angiography (CTA) is a nonin-
vasive imaging modality that rapidly determines the
presence and extent of epicardial coronary artery disease
(CAD). A normal CTA is associated with excellent
prognosis.15,16 Furthermore, CTA is able to detect other
life-threatening noncardiac causes of chest pain such as
acute aortic dissection (AAS) and PE.17
Although CMR and CTA visualize different aspects of
myocardial disease, each technique can uniquely be usedto distinguish between a coronary and noncoronary
etiology of acute chest pain and hs-cTn rise. This study
investigates whether implementing CTA or CMR early in
the diagnostic process can prevent unnecessary ICA, by
excluding significant CAD or establishing noncoronary
myocardial disease.
It is expected that in patients with suspected NSTEMI,
noncoronary myocardial disease is more frequently
diagnosed when CTA or CMR is performed early in
the diagnostic process as compared with routine clinical
management, thereby preventing unnecessary ICA. The
primary objective of the CARMENTA trial is to
investigate whether this approach reduces the total
number of patients undergoing ICA during initial
hospitalization. A secondary objective is to compare
30-day and 1-year clinical outcome to determine safety,
time to final diagnosis, cost-effectiveness, and quality of
life of each strategy.Methods
Study design and population
The CARMENTA trial (NCT01559467) is designed as a
prospective, open-label, single-center randomized controlled
clinical trial. The trial enrolls patients consecutively who
present on the emergency department (ED) with acute chest
pain, elevated serum hs-cTnT levels (N14 ng/L), and a
nondiagnostic ECG. Enrollment will continue until 288
patients have completed the study protocol. Patients are
randomized immediately after ED evaluation (comprising a
detailed medical history, physical examination, serial ECGs,
and serum hs-cTnT measurements) to 1) CMR (early in the
diagnostic process), or (2) CTA (early in the diagnostic
process), or (3) routine clinical management (without early
CMR or CTA imaging). The CARMENTA trial is a comparative
effectiveness trial evaluating the effectiveness of alternative
clinical management strategies (CMR or CTA arm) in
comparison with routine clinical care.18 Besides evaluating
the prespecified end points, that is, the number of patients
undergoing ICA during initial hospitalization, the trial design
allows evaluating the overall clinical effects of implementing
noninvasive imaging early in the diagnostic strategy in
suspected NSTEMI.
Before the start of the trial, physicians and nurses were
profoundly familiarized with the trial purpose and design to
ensure consistency in management. After CMR or CTA is
performed, a diagnosis of “coronary,” “noncoronary myocardial
disease,” or “normal/equivocal” is reported in the hospital's
electronic patient record. Additional management (ECG moni-
toring, biomarker testing, medical therapy, downstream testing,
other clinically indicated interventions) is left at the discretion of
the attending cardiologist and is in accordance with current
(institutional/European Society of Cardiology/American Heart
Association) NSTEMI guidelines. The study is conducted
according to the principles of the Declaration of Helsinki and
has been approved by the local medical ethical committee of
Maastricht University Hospital and Maastricht University.
Figure 1 illustrates the patient selection process and the
randomization strata of the CARMENTA trial.
Figure 1
Study design—flowchart patient selection. PCI, percutaneous coronary intervention.
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The primary end point of the CARMENTA trial is the total
number of patients with at least one ICA during initial admission
in each arm. Secondary end points are 30-day and 1-year clinical
outcome (a composite of major adverse cardiac events [MACEs]
and major procedure-related complications), time to final
diagnosis, cost-effectiveness, and quality of life. After 1 year,
an independent clinical end point committee (including an
interventional cardiologist, clinical cardiologist, and radiologist
[both with N5 years' experience in CMR and CTA]), blinded for
the allocated strategy, adjudicates a final diagnosis to each
patient using all available clinical and imaging data.
Clinical outcome (MACE and major procedure-related com-
plications) is defined as a composite of all-cause mortality or
cardiac mortality, recurrent MI, revascularization (percutaneous
coronary intervention and/or coronary artery bypass grafting)
not planned after the index event or congestive heart failure
requiring hospitalization, significant bleeding (fatal, intracranial,
or resulting in hemodynamic compromise; need for blood
transfusion or overt bleeding plus hemoglobin drop: minor
bleeding ≥2.0 mmol/L or [≥3 g/dL] or major bleeding ≥3.0
mmol/L [≥5 g/dL]),19 renal failure (need for temporary or
permanent hemodialysis), contrast-induced nephropathy (≥25%
or ≥44-μmol/L increase in serum creatinine from baseline),nephrogenic systemic fibrosis, allergic reaction requiring urgent
therapy, dissection/perforation/rupture after puncture of a vessel,
stroke (ischemic or hemorrhagic), or transient ischemic attack
diagnosed by a neurologist (preferably supported by imaging
techniques). MACE and major procedure-related complications
are scored during admission, and 1-month and 1-year follow up.
The definitions of recurrent MI and/or reinfarction are
adapted from the universal definition of MI.1
Costs will be assessed from a health care perspective.
Implementing CMR or CTA early in the diagnostic process is
expected to prevent unnecessary ICA and reduce the length of
hospitalization in patients with noncoronary myocardial disease.
Health care costs will be retrieved for all patients using hospital
databases and patient records. Unit costs will be based on
standard prices using the Dutch manual for cost research.20
The economic evaluation will be a cost-effectiveness analysis,
with quality-adjusted life years as an effectiveness measure. For
this purpose, health state utilities will be derived using the
EuroQol (baseline on admission and 1, 6, and 12 months after
admission).21 To investigate the cost-effectiveness of the 3
strategies, incremental cost-effectiveness ratios will be calculated.
Uncertainty surrounding the costs and effects will be examined
using nonparametric bootstrap analyses with 1,000 replications.
Cost-effectiveness acceptability curves will be derived to show
Table. Eligibility criteria
Inclusion criteria
• Prolonged symptoms suspected of cardiac origin (angina
pectoris or angina equivalent), and presentation on the
cardiac ED b24 h after symptom onset
• Increased levels of hs-cTnT (N14 ng/L; initial blood sample at
presentation or a second sample ≥3 h after presentation)
• Age 18-85 y
• Willing and capable to give written informed consent
• Written informed consent
Exclusion criteria
• Ongoing severe ischemia requiring immediate ICA (at discretion
of cardiac ED physician/cardiologist)
• Shock (mean arterial pressure b60 mm Hg) or severe heart failure
(Killip class ≥III)
• STEMI (ST elevation in 2 contiguous leads: ≥0.2 mV in men or
≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other
leads or new left bundle-branch block)
• Chest pain highly suggestive of noncardiac origin (as judged by
the cardiac ED physician/cardiologist)
◦ Acute aortic dissection
◦ Acute PE (high-risk patient defined as Wells score N6)
◦ Musculoskeletal or gastrointestinal pain
◦ Other (pneumothorax, pneumonia, rib fracture, etc)
• Previously known CAD, defined as follows:
◦ Any noninvasive diagnostic imaging test positive for CAD
(perfusion defects, and/or stress-induced wall motion abnormalities)
◦ Coronary stenosis N50% on any previous ICA or CTA
◦ Documented previous MI
◦ Documented previous coronary artery revascularization (PCI
and/or CABG)
• Known cardiomyopathy (dilated, hypertrophic, infiltrative, etc)
• Pregnancy
• Life-threatening arrhythmia on the cardiac ED or before
presentation (sustained ventricular tachycardia, repetitive
nonsustained ventricular tachycardia, ventricular fibrillation,
sinoartial or atrioventricular block)
• Atrial fibrillation
• Tachycardia (≥100 beats/min)
• Angina pectoris secondary to anemia (b5.6 mmol/L),
untreated hyperthyroidism, aortic valve stenosis (AVA
≤1.5 cm2), or severe hypertension (N200/110 mm Hg)
• Life expectancy b1 y (malignancy, etc)
• Contraindications to CMR
◦ Metallic implant (vascular clip, neurostimulator, Cochlear
implant)
◦ Pacemaker or implantable cardiac defibrillator
◦ Claustrophobia
◦ Body weight N130 kg
• Contraindication to CMR or CTA contrast agent (gadolinium
or iodine)
◦ Renal failure (estimated GFR ≤30 mL/min per 1.73 m2)/
chronic renal failure stages 4-5
◦ Known severe contrast allergy (a patient with mild
allergy is eligible for inclusion when premedication
according to hospital guidelines can be administered)
• Contraindication to adenosine
◦ High-degree atrioventricular block (second or third degree)
◦ Severe bronchial asthma
◦ Chronic obstructive pulmonary disease Gold ≥III
◦ Concomitant use of dipyridamole (Persantin)
◦ Long-QT syndrome (congenital)
PCI, Percutaneous coronary intervention; CABG, coronary artery bypass
grafting; AVA, aortic valve area; GFR, glomerular filtration rate.
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possible maximum values a decision maker is willing to pay for a
quality-adjusted life year.22
Eligibility criteria
The detailed inclusion and exclusion criteria are shown in
Table. All consecutive patients are screened for eligibility on the
ED by cardiologists in training and their supervisors, 24 hours a
day, 7 days per week, whole year-round. Inclusion and
randomization of eligible patients are performed on week days
from 8:00 AM until 6:00 PM (office hours). Patients presenting on
the ED with suspected NSTEMI (ie, prolonged angina pectoris or
symptoms equivalent to angina, normal or nondiagnostic ECG,
and increased levels of hs-cTnT [N14 ng/L on admission or 3
hours later]) are eligible. Patients with shock, ongoing severe
ischemia requiring immediate ICA, or chest pain highly
suggestive of noncardiac origin (eg, musculoskeletal and
gastrointestinal) are excluded. In addition, patients with
previously known CAD or cardiomyopathy and patients
experiencing angina pectoris secondary to anemia, severe aortic
valve stenosis, severe hypertension, or tachycardia (type II MI)
are excluded.1 A log of all patients screened for eligibility is kept,
including all ineligible and eligible patients but who declined
participation or dropped out.
The Netherlands Heart Foundation sponsors the CARMENTA
trial. The authors are solely responsible for the design and
conduct of this study, all study analyses, and drafting and editing
of the manuscript, and its final contents.
Randomization
Patients are randomized immediately after initial ED
evaluation and after obtaining informed consent. Patients
are randomized in a 1:1:1 fashion to one of the following
strategies: (1) CMR, or (2) CTA early in the diagnostic
process, or (3) routine clinical management without early
noninvasive imaging. A stratified randomization method
is used to equally distribute patients with an hs-cTnT
concentration of 15 to 50 ng/L and patients with an hs-
cTnT concentration of N50 ng/L (based on the highest hs-
cTnT value of the first 2 blood samples) among 1 of the 3
strategies. Variable block randomization (3, 6, or 9
patients per block) is assembled to safeguard equal
distribution of patients equally over time and to prevent
prediction of allocation of patients.
Randomization is performed with TENALEA randomi-
zation software (FormsVision BV, Abcoude, The Nether-
lands) provided by the Clinical Trial Center Maastricht.
The software is an Internet-based service supporting
online patient registration and randomization. The online
randomization module includes comprehensive report-
ing tools, audit tools, and tools for monitoring operational
system components.
Patient care (treatment) in randomization arms
Randomization arm 1: routine clinical care. In the
routine clinical management arm, patients are not
Figure 2
Recommendations to guide clinical management in clinical routine arm. *If appropriate according to clinical judgment and in the absence of
regular contra-indications. †If coronary angiography results are ambiguous. ‡Current guidelines: European Society of Cardiology, American
College of Cardiology, Netherlands Society of Cardiology and local hospital protocols.
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admitted and treated according to current guidelines and
clinical judgment. The decision to proceed to ICA, and
additional downstream testing is made on clinical
grounds and left at the discretion of the clinical
cardiologist taking care of the patient. Recommendations
are provided to prevent heterogeneity between attending
cardiologists (Figure 2).
Randomization arm 2: CMR imaging. A compre-
hensive CMR study is performed on a clinical whole-body
3.0-T multitransmit magnetic resonance imaging scanner
(Achieva; Philips Medical Systems, Best, The Netherlands)
as soon as possible after admission (b72 hours). A bright
blood sequence in the transversal plane covering the
whole heart and large vessels is used to determine
anatomy and extracardiac pathology. Cine-CMR in the
short axis (multislice, covering the whole heart), left
ventricular outflow tract, and horizontal and vertical long-
axis view (single slice) is used to evaluate ventricular
volumes, regional wall motion abnormalities, and overall
function. T2-weighted CMR in short-axis view (multislice,
covering the whole heart), horizontal and vertical long-
axis view (single slice), and adenosine-stress-rest perfu-
sion CMR (basal, mid, and apical slice) and DE-CMR in
short axis (multislice, covering the whole heart) andhorizontal and vertical long axis (single slice) are used to
detect edema, ischemia, and/or scar, respectively. All
images are reviewed step by step during scanning.
Additional nonstandardized images are obtained when
observations during standardized views remain ambigu-
ous. Gadolinium contrast infusion (Gadovist 0.2 mmol/kg
body weight; Bayer Pharma AG, Berlin, Germany) is used
for perfusion and DE-CMR imaging. A coronary etiology
of chest pain is assumed in case of the following:
subendocardial or transmural late enhancement on DE-
CMR in the territory of a coronary artery with/without
regional wall motion abnormalities on cine, with/without
obvious increased signal intensity on T2-weighted-CMR,
and/or a subendocardial or transmural perfusion defect
corresponding to the distribution territory of a coronary
artery during rest and/or stress perfusion.
Randomization arm 3: CTA. A comprehensive CT
scanning investigation is performed using a second-
generation dual-source CT scanner (Somatom Definition
Flash; Siemens Medical Solutions, Forchheim, Germany)
as soon as possible after admission (b72 hours). To
achieve a stable heart rate of b65 beats/min, patients will
be premedicated with beta blocking agents (if no
contraindications, 50 mg metoprolol oral and up to
20 mg metoprolol intravenously before the scan).
Figure 3
Recommendations to guide clinical management in CMR or CTA arm. *Cardiomyopathy (Takotsubo, hypertrophic, dilated, infiltrative),
myocarditis, pericarditis, aortic dissection, acute PE. †If appropriate according to clinical judgment and in the absence of contraindications. ‡Left at
the discretion of caring cardiologist. §Current guidelines: European Society of Cardiology, American College of Cardiology, Netherlands Society
of Cardiology and local hospital protocols.
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maximal vasodilatation to enhance coronary lumen
visualization before scanning.
A nonenhanced scan is performed to determine the
coronary calcium score, using the method of Agatston
et al.23 A testbolus is used to ensure optimal timing for
CTA. Computed tomography angiography is performed
using a dual-head injector contrast protocol (Ultravist
300; Bayer Pharma AG, Berlin, Germany) with a total
amount of 120 mL to facilitate sufficient late-enhance-
ment imaging. Every patient in the CTA arm will undergo
a non-contrast baseline CT scan, coronary CTA, and, for
experimental reasons, DE imaging.
In patients with a stable heart rate b65 beats/min, a
prospectively triggered high-pitch spiral protocol is
used. In patients with a heart rate ≥65 beats/min or in
case of an irregular heart rhythm, a retrospectively
gated helical protocol with dose modulation is used.
Dual-energy DE images are acquired 6 minutes after
contrast injection using a prospectively gated dual-
energy scanning protocol. Images are reconstructed
with thin slices, and field of view and reconstruction
kernel are adapted to evaluate the coronary arteries, to
assess the whole lung, pulmonary arteries, and theaorta. Images are directly viewed and evaluated on a
dedicated postprocessing workstation (MultiModality
Workplace; Siemens Medical Solutions).
A coronary etiology of the chest pain syndrome is
considered highly likely in case of the following: a
significant stenosis (≥70% luminal narrowing) or total
occlusion in a coronary artery. Also, an Agatston score of
more than 1,000 will be considered as evidence of a
coronary etiology, in the absence of AAS, PE, or
alternative causes.
Cardiovascular magnetic resonance and CTA analysis
and recommendations
For both CMR and CTA, the following noncoronary
myocardial disease diagnoses are made: (peri)myocardi-
tis, stress cardiomyopathy, other cardiomyopathies (eg,
amyloidosis and sarcoidosis), AAS, PE, and other (non-)
cardiac (incidental) findings. A CMR of CTA investigation
is “equivocal”when the images are nondiagnostic, owing
to insufficient image quality (artifacts) or incomplete
image acquisition, and when a final diagnosis cannot
be made. A CMR or CTA study is interpreted as “normal”
if the images are diagnostic and no (extra-)cardiac
pathology is seen.
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neously and routinely by 2 experienced readers, a
cardiologist and a radiologist, to come to a diagnosis
including extracardiac diagnosis. During scanning, a
step-by-step algorithm is followed, such that at each
point, the scan can be interrupted after a diagnosis is
made to minimize study scan duration and minimize
hazard for the patient.
Immediately after the investigation, diagnostic informa-
tion from CMR or CTA will be reported in the electronic
hospital records (time stamped) and the responsible
clinician notified. The final decision to perform additional
diagnostic testing or intervention is left at the discretion
of the attending cardiologist. Recommendations are
provided to prevent heterogeneity between supervising
cardiologists (Figure 3).
Patient safety
An independent statistician will perform an interim
analysis after 50, 100, and 200 included patients, to reduce
the risk of exposure of study participants to a possibly
inferior strategy. The results of this interim analysis will be
reported to the medical ethical committee. For patient
safety, MACE rate (all-cause death, revascularization not
planned during the initial admission, re-admission for
heart failure, and recurrent MI between groups will be
compared. The CMR or CTA arm will be discontinued in
case the interim analysis shows a significant (P b .05)
increase in MACE in patients in either arm. No additional
patients will be randomized to the inferior strategy, but
the other 2 strategies (CMR or CTA vs routine clinical
care) will be continued. The follow-up of included
patients will continue even if the inclusion of new
patients is stopped. After randomization, the cardiologist
taking care of the patient can deviate from the study
protocol at all times. If other urgent diagnostics or
therapeutics than prescribed by the study protocol are
necessary, this will receive priority. Protocol violations
will be reported.Sample size calculation
The primary end point of the present study is a
reduction in total number of patients with at least 1 ICA
during initial admission by the application of noninvasive
diagnostic imaging techniques CMR or CTA early in the
diagnostic process as compared with routine clinical
management. The primary comparison groups in this
randomized controlled trial are, therefore, CMR vs
standard care and CTA vs standard care.
Based on clinical experience, approximately 75% of
admitted patients with NSTEMI undergo ICA during
initial hospitalization. This is supported by data from the
CRUSADE and ACTION registry, reporting an overall
rate of in-hospital ICA of 73% and 80%, respectively.24,25Trials such as the ICTUS, CRUSADE, FRISC II, PURSUIT,
TIMI IIIB, GRACE, and MATE report that up to 7% to
25% of patients with clinically suspected MI have
normal coronary arteries or insignificant disease at ICA
and may ultimately be diagnosed as having noncoronary
myocardial disease.26 It is expected that these numbers
will increase when using the new hs-cTn assays to
detect myocardial injury. Early noninvasive imaging
(either CMR or CTA) may filter out noncoronary
myocardial disease, reducing the need for ICA to
approximately 60% of patients. Ninety-six patients per
treatment arm with completed study protocols will be
sufficient to detect this difference in proportions with a
power of 80% and α value of .05. Accounting for a
dropout rate of 10%, it is assumed that in total, 321
patients have to be enrolled.
Data analysis
For all 3 groups, the relative risk of ICA will be
calculated. To evaluate the primary objective, the total
number of patients with at least one ICA during the initial
admission will be compared between groups by χ2
analysis. Comparison will be done between a CMR-guided
approach vs standard care, a CTA-guided approach vs
standard care, and a CMR vs a CTA-guided approach.
Multivariable logistic regression models will be used to
adjust for potential confounders.
To assess clinical outcome (a composite of MACEs and
major procedure-related complications) over time,
Kaplan-Meier plots will be constructed and groups will
be compared by using a log-rank test. To assess clinical
outcome, Cox regression models will be fitted to adjust
for confounders. A prespecified secondary analysis will be
performed on the effect of hs-cTnT level and patient age
on the primary and secondary end points. Prespecified
subgroups are the following: hs-cTnT (15-50 and N50 ng/L)
and age (b60 and ≥60 years).
Differences between the 3 groups in quality of life will
be reported descriptively. In addition, differences be-
tween the randomization groups in both generic and
disease-specific quality of life will be tested using analysis
of variance.
Summary
The CARMENTA trial investigates whether the imple-
mentation of CMR or CTA early in the diagnostic
process in patients presenting with acute chest pain,
nondiagnostic or normal ECG, and elevated hs-cTnT
levels (ie, suspected NSTEMI) leads to an early
alternative diagnosis than MI (eg, myocarditis, PE, etc)
as compared with routine clinical management. Conse-
quently, this could prevent unnecessary ICA and
associated complications and reduce length of hospital-
ization and costs, without having a detrimental effect on
clinical outcome. Especially in the current era of hs-cTn
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specificity for acute MI than conventional (fourth
generation) troponin assay, this trial may have important
implications for the future diagnostic workup of patients
with suspected but not yet proven NSTEMI.References
1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of
myocardial infarction. Circulation 2012;126:2020-35.
2. Wang K, Asinger RW, Marriott HJ. St-segment elevation in conditions
other than acute myocardial infarction. N Engl J Med 2003;349:
2128-35.
3. Agewall S, Giannitsis E, Jernberg T, et al. Troponin elevation in
coronary vs. non-coronary disease. Eur Heart J 2011;32:
404-11.
4. Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in
the distinction of acute myocardial infarction from acute cardiac
noncoronary artery disease. Circulation 2012;126:31-40.
5. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of
myocardial infarction with sensitive cardiac troponin assays. N Engl J
Med 2009;361:858-67.
6. Keller T, Zeller T, Peetz D, et al. Sensitive troponin i assay in early
diagnosis of acute myocardial infarction. N Engl J Med 2009;361:
868-77.
7. Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular
magnetic resonance in patients presenting with chest pain, raised
troponin, and unobstructed coronary arteries. Eur Heart J 2007;28:
1242-9.
8. Morrow DA. Clinical application of sensitive troponin assays. N Engl
J Med 2009;361:913-5.
9. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of mri delayed
contrast enhancement to irreversible injury, infarct age, and
contractile function. Circulation 1999;100:1992-2002.
10. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement
cardiovascular magnetic resonance assessment of non-ischaemic
cardiomyopathies. Eur Heart J 2005;26:1461-74.
11. Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting acute coronary
syndrome in the emergency department with cardiac magnetic
resonance imaging. Circulation 2003;107:531-7.
12. Plein S, Greenwood JP, Ridgway JP, et al. Assessment of non–ST-
segment elevation acute coronary syndromes with cardiac magnetic
resonance imaging. J Am Coll Cardiol 2004;44:2173-81.
13. Laraudogoitia Zaldumbide E, Perez-David E, Larena JA, et al. The
value of cardiac magnetic resonance in patients with acute coronary
syndrome and normal coronary arteries. Rev Esp Cardiol 2009;62:
976-83.14. Leurent G, Langella B, Fougerou C, et al. Diagnostic contributions of
cardiac magnetic resonance imaging in patients presenting with
elevated troponin, acute chest pain syndrome and unobstructed
coronary arteries. Arch Cardiovasc Dis 2011;104:161-70.
15. Meijboom WB, Mollet NR, Van Mieghem CA, et al. 64-Slice ct
coronary angiography in patients with non–ST elevation acute
coronary syndrome. Heart 2007;93:1386-92.
16. Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, et al. Diagnostic
performance of multidetector ct angiography for assessment of
coronary artery disease: meta-analysis. Radiology 2007;244:
419-28.
17. Takakuwa KM, Halpern EJ. Evaluation of a “triple rule-out” coronary
ct angiography protocol: use of 64-section ct in low-to-moderate risk
emergency department patients suspected of having acute coronary
syndrome. Radiology 2008;248:438-46.
18. Hlatky MA, Douglas PS, Cook NL, et al. Future directions for
cardiovascular disease comparative effectiveness research: report of
a workshop sponsored by the national heart, lung, and blood
institute. J Am Coll Cardiol 2012;60:569-80.
19. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding
definitions for cardiovascular clinical trials: a consensus report from
the bleeding academic research consortium. Circulation 2011;123:
2736-47.
20. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM, et al. Handleiding
voor kostenonderzoek. Methoden en standaard kostprijzen voor
economische evaluaties in de gezondheidszorg. College voor
zorgverzekeringen. Geactualiseerde versie 2010.
21. The EuroQol Group. Euroqol—a new facility for the measurement of
health-related quality of life. The euroqol group. Health Policy 1990;
16:199-208.
22. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and c/e-ratios
alongside a clinical trial. Health Econ 1994;3:309-19.
23. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of
coronary artery calcium using ultrafast computed tomography. J Am
Coll Cardiol 1990;15:827-32.
24. Ryan JW, Peterson ED, Chen AY, et al. Optimal timing of
intervention in non–ST-segment elevation acute coronary
syndromes: insights from the crusade (can rapid risk stratification
of unstable angina patients suppress adverse outcomes with early
implementation of the ACC/AHA guidelines) registry. Circulation
2005;112:3049-57.
25. Leonardi S, Chen AY, Gharacholou SM, et al. Limitations of using
cardiac catheterization rates to assess the quality of care for patients
with non–ST-segment elevation myocardial infarction. Am Heart J
2012;164:502-8.
26. Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular magnetic
resonance in patients with myocardial infarction: current and
emerging applications. J Am Coll Cardiol 2009;55:1-16.
